多发性骨髓瘤的二线治疗:一个SEER医疗保险分析
Matthew R LeBlanc1, Xi Zhou2, Christopher D Baggett2
1University of North Carolina at Chapel Hill School of Nursing, Chapel Hill, North Carolina, USA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
Clinical lymphoma, myeloma & leukemia
|May 17, 2024
概括
在复发性/耐药性多发性骨髓瘤 (RRMM) 治疗中,改善的生存率与成本上升有关. 较新的疗法提供了更好的结果,但对RRMM患者来说,医疗费用显著增加.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
背景情况:
- 复发性/耐药性多发性骨髓瘤 (RRMM) 的治疗环境自2012年以来随着众多药物批准而显著发展.
- 在治疗选择,生存和成本方面,对人口层面的趋势进行表征对于理解治疗演变至关重要.
研究的目的:
- 分析治疗选择的趋势,整体存活率和复发/耐药多发性髓瘤患者的成本.
- 评估新疗法对治疗结果和医疗保健支出随时间推移的影响.
主要方法:
- 利用了SEER-Medicare数据库 (2007-2017年) 包括9,822名患有多发性骨髓瘤 (MM) 的成年患者.
- 确定了MM导向的疗法和疗法线,重点是二线疗法 (2LT) 方案.
- 使用考克斯比例危险模型分析整体生存趋势,使用JoinPoint分析分析成本趋势.
主要成果:
- 近60%的患者接受了2LT,其中46%的2LT疗法包括2012年后批准的药物.
- 晚年2LT的开始与改善的整体存活率 (HR0.78每5年) 有关.
- 2LT的平均通货膨胀调整后成本在2012年后大幅增加,其中包含新药剂的疗法成本更高 (224,193美元与189,381美元).
结论:
- 开始二线治疗的RRMM患者的整体存活率有所改善.
- 这种生存率的提高伴随着治疗成本的大幅增加,特别是新药.
- 这些发现为评估RRMM管理中的当前和未来药物批准提供了必要的背景.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.1K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K